病灶内维拉帕米与曲安奈德治疗增生性瘢痕和瘢痕疙瘩的荟萃分析
该荟萃分析纳入7项随机对照试验共461例患者,比较病灶内注射维拉帕米与曲安奈德治疗增生性瘢痕和瘢痕疙瘩的疗效与安全性。结果显示曲安奈德在首次治疗后对高度和柔韧性的改善更快,但后续治疗无显著差异;维拉帕米组毛细血管扩张和皮肤萎缩的发生率显著更低,总不良反应无显著差异。维拉帕米可能成为曲安奈德的有效替代。
要点
- 曲安奈德首次治疗后对瘢痕高度和柔韧性的改善优于维拉帕米。
- 后续治疗中两药在高度、色素沉着、血管分布和柔韧性上无显著差异。
- 维拉帕米组毛细血管扩张和皮肤萎缩发生率显著低于曲安奈德。
核心结论
- 维拉帕米可能成为曲安奈德的有效替代,总不良反应无显著差异,但毛细血管扩张和皮肤萎缩发生率更低。
研究设计与样本
- 荟萃分析纳入7项随机对照试验,共461例增生性瘢痕或瘢痕疙瘩患者。
- 检索Embase、Google Scholar和PubMed从建库至2020年2月。
- 纳入评估温哥华瘢痕量表疗效或报告不良反应的随机对照试验。
- 连续数据以均数差(MD)分析,二分类变量以相对危险度(RR)分析。
主要发现
- 与维拉帕米相比,曲安奈德首次治疗后瘢痕高度变化(MD=0.07;P<0.05)和柔韧性变化(MD=0.23;P<0.05)更显著。
- 后续治疗中两组在高度、色素沉着、血管分布和柔韧性变化上无显著差异。
- 总不良反应无显著差异(RR=0.42;P=0.1)。
- 亚组分析显示维拉帕米组毛细血管扩张(RR=0.04;P<0.05)和皮肤萎缩(RR=0.10;P<0.05)发生率显著低于曲安奈德组。
- 疼痛发生率两组无显著差异(RR=1.27;P=0.77)。
关键数值与推荐
- 曲安奈德首次治疗后瘢痕高度变化MD=0.07(P<0.05),柔韧性变化MD=0.23(P<0.05)。
- 总不良反应RR=0.42(P=0.1)。
- 毛细血管扩张RR=0.04(P<0.05),皮肤萎缩RR=0.10(P<0.05),疼痛RR=1.27(P=0.77)。
临床怎么用
- 对于增生性瘢痕和瘢痕疙瘩,维拉帕米可作为曲安奈德的有效替代方案。
- 需快速改善瘢痕高度和柔韧性时可优先考虑曲安奈德首次治疗。
- 关注长期治疗中毛细血管扩张和皮肤萎缩风险时,维拉帕米可能更优。
局限性
- 纳入随机对照试验仅7项,样本量有限。
- 检索截止至2020年2月,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical treatment of hypertrophic scars (HSs) and keloids is often unsatisfactory. Intralesional injections of triamcinolone acetonide (TAC) and verapamil are widely used to treat HSs and keloids, but their efficacy and safety are controversial. OBJECTIVES: The aim of this study was to conduct a meta-analysis of the effectiveness and safety of verapamil and TAC in the treatment of HSs and keloids. METHODS: Embase, Google Scholar, and PubMed were searched for randomized controlled trials (RCTs) from inception to February 2020. RCTs that evaluated treatment effects with the Vancouver Scar Scale or reported adverse effects were included. The continuous data and the dichotomous variables were analyzed as mean difference (MD) and relative risk (RR), respectively. RESULTS: Seven RCTs (461 patients) were included. Compared with verapamil, TAC rapidly changed the ∆height (MD = 0.07; P < 0.05) and ∆pliability (MD = 0.23; P < 0.05) after the first session, but subsequent treatments resulted in no significant differences in the ∆height, ∆pigmentation, ∆vascularity, and ∆pliability. Although total adverse effects (RR = 0.42; P = 0.1) were not significantly different, in the subgroup analysis the incidence of telangiectasia (RR = 0.04; P < 0.05) and skin atrophy (RR = 0.10; P < 0.05), but not pain (RR = 1.27; P = 0.77), was significantly lower with verapamil than with TAC. CONCLUSIONS: Verapamil may be an effective substitute for TAC. Although total adverse effects did not change, the incidence of telangiectasia and skin atrophy was lower with verapamil than with TAC.
引用
- Wang P, Gu L, Bi H, et al. Comparing the Efficacy and Safety of Intralesional Verapamil With Intralesional Triamcinolone Acetonide in Treatment of Hypertrophic Scars and Keloids: A Meta-Analysis of Randomized Controlled Trials. Aesthet Surg J. 2021. PMID: 33313652. doi:10.1093/asj/sjaa357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。